A Chart Review to Evaluate the Safety and Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) on Subjects With Autism Spectrum Disorder (ASD)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Autistic Disorder
- Sponsor
- Wave Neuroscience
- Enrollment
- 141
- Locations
- 1
- Primary Endpoint
- Childhood Autism Rating Scale (CARS)
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) on subjects with Autism Spectrum Disorder (ASD).
Detailed Description
This is a retrospective chart review of 200 consecutive charts of subjects ages 2-20 years old seen at the Brain Treatment Center between 2010 and 2015. The review is designed to evaluate the safety and efficacy of Magnetic Electroencephalogram/Electrocardiogram(EEG/ECG)-Guided Resonance Therapy (MeRT) on subjects with Autism Spectrum Disorder (ASD).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must have completed a baseline EEG at the Brain Treatment Center (BTC)
- •Age between 2 and 20 years old at initial visit
- •Must have a diagnosis of ASD according to the prevailing standard at that time (i.e., Diagnostic and Statistical Manual-IV (DSM-IV)) (ASD Group only)
- •Must have received Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) for more than (5) sessions (ASD Group only)
Exclusion Criteria
- •Clinically significant abnormality or clinically significant unstable medical condition during treatment that in the Investigator's judgment may have may limited interpretation of the results.
Outcomes
Primary Outcomes
Childhood Autism Rating Scale (CARS)
Time Frame: Baseline through study completion, an average of 36 months
Symptom reduction in ASD will be measured using the reduction in the CARS between two time points: Baseline (BL) CARS and Final CARS Evaluation.
Secondary Outcomes
- Electrophysiological(Baseline through study completion, an average of 36 months)